Private Equity Physician Practice Deals Just Fell by Half. Here's What It Means If You're Selling, Employed, or Considering an Offer (2026)

For most of the last decade, private equity's move into physician practices ran in one direction: up and to the right. PitchBook's deal data captures the scale of it — physician practice management acquisitions climbed to a peak of 851 deals in 2021. Then the trend reversed, and in 2026 it broke.

Physician practice management is on track to record roughly half the deals this year that it saw in 2025, with just 105 deals in the first half of 2026. Narrow the lens to the specific transactions that let PE firms take control of a practice's management services — the billing, scheduling, and operational backbone — and the year-over-year drop is nearly 36 percent, from 111 such deals in the second quarter of 2025 to 71 in the same quarter of 2026. Across healthcare services broadly, PE deal volume fell 18.5 percent year over year. But physician practice management — the corner of healthcare where private equity had built its largest presence — got hit hardest.

This isn't a rumor or a projection from an interested party. It's PitchBook transaction data, reported independently by STAT, Stateline, Governing, and multiple state policy outlets within the last two weeks. The decline is real, it's large, and the reason behind it is unusually clear.

To understand why the deals dried up, you have to understand how they were structured in the first place — which is worth doing anyway, because it's the same structure sitting underneath any PE-backed job offer you might evaluate.

Nearly every state has a Corporate Practice of Medicine (CPOM) doctrine — a legal rule barring corporations and non-physician investors from owning medical practices, employing physicians for clinical care, or influencing clinical decisions. Private equity worked around it with a structure our selling to private equity guide and California Professional Medical Corporation guide both describe: the practice's clinical entity (the PC) stays nominally owned by a licensed physician — sometimes called the "friendly physician" — while a separate management services organization (the MSO), owned by the PE firm, controls billing, scheduling, real estate, IT, and business operations. The physician owns the medicine on paper. The PE firm owns everything around it, and captures the economics through the management contract.

That structure is exactly what the new state laws target. And 2026 is the year the most aggressive ones took effect:

• ✔California led, with two laws effective January 1, 2026. SB 351 codified the CPOM doctrine into statute and explicitly prohibits non-physician investors from influencing clinical decision-making, while AB 1415 expanded the notice obligations requiring certain MSO and PE healthcare transactions to be reported to the state — the full regulatory picture is laid out in Bloomberg Law's analysis.
• ✔Oregon enacted restrictions, also effective January 2026, specifically aimed at the friendly-physician model — limiting MSO control over scheduling, physician compensation, coding, billing, and payer terms, to keep licensed physicians genuinely in charge rather than nominally so.
• ✔At least 25 states have now proposed or passed laws increasing oversight of healthcare transactions, restricting non-physician control of practices, or limiting how PE firms roll up medical groups. Pennsylvania's proposed Healthcare System Protection Act would empower its attorney general to block acquisitions outright.

PitchBook's own analysts named the mechanism plainly: these laws are lengthening transaction timelines, increasing deal costs and complexity, and — critically — making the serial "roll-up" strategy (buying many small practices and consolidating them into one large platform) much harder to execute. Roll-ups were the entire engine of PE's physician-practice thesis. Slow that engine in enough states, and deal volume falls exactly the way the data shows it falling.

The headline "PE deals are down 50%" can read two ways for a practice owner, and it's worth separating them.

The market is more cautious, but not closed. Well-run specialty groups are still transacting, and pricing for the strongest practices has held up — competition for high-quality groups continues to drive double-digit EBITDA multiples in several specialties even as the overall deal count falls. This isn't a collapse in valuations across the board. It's a collapse in deal volume, concentrated in the management-control transactions that new state laws made harder.

But the deals that do happen look different now, and less favorably for the seller. Current market reporting describes 2026 deal structures demanding meaningfully more from physician sellers than the 2021–2022 peak did: rollover equity requirements of 20 to 40 percent (meaning you keep a large chunk of your proceeds invested in the buyer's entity rather than cashing out), longer earn-out periods, regulatory escrows, and tighter management-incentive terms. In plain terms, the buyer wants you to keep more skin in the game, for longer, with more of your payout riding on future performance and regulatory outcomes you don't fully control.

The practical takeaways for a physician owner:

• ✔If you're in a state that just tightened CPOM rules — California, Oregon, and a growing list — a deal structured under last year's assumptions may not close the same way, or at all. The structure your advisor modeled in 2024 may not even be legal in 2026.
• ✔Timelines and costs have risen, which means the transaction itself consumes more of your time, attention, and legal spend before you see a dollar. Budget for that.
• ✔Rollover equity is the number to scrutinize. A headline sale price with 40 percent rollover is a fundamentally different deal from the same price with 10 percent rollover — far more of your outcome depends on the buyer's future performance and their ability to navigate the exact regulatory environment tightening around them. Model your actual take-home under realistic scenarios, not the headline number.
• ✔Third-party diligence matters more than ever. The regulatory complexity means the quality of your transaction advisors — healthcare M&A attorneys who know your state's current CPOM rules specifically — is doing more work than it did in a simpler market.

None of this means don't sell. It means the honest version of the decision has changed, and the full economics of a PE practice sale deserve a fresh look under 2026 conditions rather than 2022 assumptions.

Most physicians affected by this trend don't own their practice — they work at one a PE firm already bought. For you, the slowdown carries a different set of implications.

The same regulatory pressure slowing new deals also applies to the group you already work for. State laws restricting MSO control over physician compensation, scheduling, coding, and billing are designed to return clinical and operational authority to licensed physicians. If you're at a PE-backed group in a state that just enacted these rules, the terms of how your group operates — how your compensation is structured, how much say physicians have in clinical operations — may be shifting, generally in physicians' favor. It's worth watching how your specific employer responds.

There's a stability question underneath it, too. If your group's growth strategy — and often its financial footing, and the assumptions baked into your compensation model — depended on continued acquisition and consolidation, a market where roll-ups have gotten harder is a market where that strategy faces headwinds. This is the same employer-stability due diligence that matters for any employed physician, applied to the PE-backed context.

One quieter consequence works in your favor: when PE firms find it harder and more expensive to acquire and consolidate practices, retaining the physicians they already employ becomes more valuable to them. That's no guarantee of anything, but it's a reason to walk into your next contract negotiation knowing your continued presence has real value to an employer whose growth options just narrowed.

If you're evaluating a job offer from a private-equity-owned practice right now — as a resident finishing training, or an attending considering a move — this news should sharpen a few questions rather than scare you off.

Ask directly about the group's regulatory exposure: which states it operates in, and how it's adapting to the CPOM and transaction-oversight laws taking effect. A group with a thoughtful answer is in better shape than one that hasn't reckoned with the shift.

Then scrutinize any equity component of your offer. PE-backed groups often dangle equity or a "partnership track" as part of the pitch. In a market where the roll-up-and-sell exit strategy has gotten harder and deal multiples have eased from their peak, the realistic future value of that equity deserves genuine skepticism. Model it conservatively, and don't let a speculative equity upside paper over a below-market base salary — our partnership buy-in guide covers how to evaluate these arrangements honestly.

Above all, weight the concrete parts of the offer more heavily than the exit-driven upside. In a tighter deal environment, your salary, call schedule, non-compete, tail coverage, and termination terms matter more than the speculative promise of a future liquidity event that's now harder for the PE firm to engineer in the first place.

Private equity's decade-long expansion into physician practices was built on two things: cheap capital and regulatory arbitrage — the friendly-physician structure that let non-physician investors capture practice economics around CPOM rules. Higher interest rates pressured the first. A coordinated wave of state legislation is now pressuring the second, and 2026's deal data is the first clear, quantified evidence of the effect: physician practice management, the sector where PE went deepest, is where the pullback is sharpest.

For physicians, this isn't clearly good news or bad news — it's both, depending on where you sit. The laws driving the shift are largely designed to protect physician clinical autonomy, which most physicians will regard as a genuine win. But the same forces reshape the financial calculus of selling a practice, working at a PE-backed group, or accepting an offer from one — generally rewarding concrete, present-value terms over speculative future upside, and putting a real premium on understanding your specific state's rapidly changing rules.

This story is still developing. At least 25 states have legislation in motion, and the 2026 data covers only the first half of the year. Expect the regulatory environment — and the deal numbers — to keep moving, and check the current state of your own state's law before making any decision this analysis touches. We'll update this piece as the second-half figures and new state laws land.